letrozole + tecemotide

Letrozole + tecemotide is a combination therapy approach that pairs letrozole, a third-generation aromatase inhibitor, with tecemotide, a MUC1-targeted cancer vaccine. Letrozole works by decreasing estrogen production through aromatase inhibition, which is particularly effective in hormone receptor-positive breast cancers. Tecemotide (formerly known as L-BLP25 or Stimuvax) is a synthetic lipopeptide vaccine designed to induce a cellular immune response against cancer cells expressing MUC1, a glycoprotein that is overexpressed in many cancers including breast cancer. The combination has been investigated in clinical trials for the treatment of breast cancer, particularly in the neoadjuvant setting.

Other names

L-BLP25 + letrozoleStimuvax + letrozoleBLP25 liposome vaccine + letrozoleemepepimut-S + letrozole